flamingo pharma (uk) ltd
flamingo pharma (uk) ltd Company Information
Company Number
09006526
Next Accounts
Dec 2025
Shareholders
flamingo pharmaceuticals limited
Group Structure
View All
Industry
Wholesale of pharmaceutical goods
Registered Address
first floor kirkland house, 11-15 peterborough road, harrow, middlesex, HA1 2AX
Website
www.flamingopharma.co.ukflamingo pharma (uk) ltd Estimated Valuation
Pomanda estimates the enterprise value of FLAMINGO PHARMA (UK) LTD at £15.2m based on a Turnover of £27.5m and 0.55x industry multiple (adjusted for size and gross margin).
flamingo pharma (uk) ltd Estimated Valuation
Pomanda estimates the enterprise value of FLAMINGO PHARMA (UK) LTD at £5.9m based on an EBITDA of £1.1m and a 5.58x industry multiple (adjusted for size and gross margin).
flamingo pharma (uk) ltd Estimated Valuation
Pomanda estimates the enterprise value of FLAMINGO PHARMA (UK) LTD at £5.9m based on Net Assets of £3.1m and 1.92x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Flamingo Pharma (uk) Ltd Overview
Flamingo Pharma (uk) Ltd is a live company located in harrow, HA1 2AX with a Companies House number of 09006526. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in April 2014, it's largest shareholder is flamingo pharmaceuticals limited with a 100% stake. Flamingo Pharma (uk) Ltd is a established, large sized company, Pomanda has estimated its turnover at £27.5m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Flamingo Pharma (uk) Ltd Health Check
Pomanda's financial health check has awarded Flamingo Pharma (Uk) Ltd a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 8 areas for improvement. Company Health Check FAQs
2 Strong
2 Regular
8 Weak
Size
annual sales of £27.5m, make it in line with the average company (£25.1m)
£27.5m - Flamingo Pharma (uk) Ltd
£25.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 65%, show it is growing at a faster rate (5.6%)
- Flamingo Pharma (uk) Ltd
5.6% - Industry AVG
Production
with a gross margin of 15.2%, this company has a higher cost of product (26.5%)
15.2% - Flamingo Pharma (uk) Ltd
26.5% - Industry AVG
Profitability
an operating margin of 3.1% make it less profitable than the average company (3.9%)
3.1% - Flamingo Pharma (uk) Ltd
3.9% - Industry AVG
Employees
with 12 employees, this is below the industry average (37)
12 - Flamingo Pharma (uk) Ltd
37 - Industry AVG
Pay Structure
on an average salary of £109.6k, the company has a higher pay structure (£75.4k)
£109.6k - Flamingo Pharma (uk) Ltd
£75.4k - Industry AVG
Efficiency
resulting in sales per employee of £2.3m, this is more efficient (£674.5k)
£2.3m - Flamingo Pharma (uk) Ltd
£674.5k - Industry AVG
Debtor Days
it gets paid by customers after 61 days, this is near the average (59 days)
61 days - Flamingo Pharma (uk) Ltd
59 days - Industry AVG
Creditor Days
its suppliers are paid after 13 days, this is quicker than average (31 days)
13 days - Flamingo Pharma (uk) Ltd
31 days - Industry AVG
Stock Days
it holds stock equivalent to 135 days, this is more than average (62 days)
135 days - Flamingo Pharma (uk) Ltd
62 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (10 weeks)
0 weeks - Flamingo Pharma (uk) Ltd
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 77.9%, this is a higher level of debt than the average (54%)
77.9% - Flamingo Pharma (uk) Ltd
54% - Industry AVG
FLAMINGO PHARMA (UK) LTD financials
Flamingo Pharma (Uk) Ltd's latest turnover from March 2024 is £27.5 million and the company has net assets of £3.1 million. According to their latest financial statements, Flamingo Pharma (Uk) Ltd has 12 employees and maintains cash reserves of £135.8 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 27,455,612 | 16,470,873 | 865,308 | |||||||
| Other Income Or Grants | ||||||||||
| Cost Of Sales | 23,283,390 | 14,422,528 | 970,141 | 11,454 | ||||||
| Gross Profit | 4,172,222 | 2,048,345 | -104,833 | -11,454 | ||||||
| Admin Expenses | 3,331,865 | 1,309,739 | 506,194 | 20,801 | ||||||
| Operating Profit | 840,357 | 738,606 | -611,027 | -32,255 | ||||||
| Interest Payable | 52,038 | 61,860 | 38,677 | 5,380 | ||||||
| Interest Receivable | ||||||||||
| Pre-Tax Profit | 788,494 | 676,746 | -649,704 | -37,635 | ||||||
| Tax | -198,085 | -126,677 | 236,069 | 7,527 | ||||||
| Profit After Tax | 590,409 | 550,069 | -413,635 | -30,108 | ||||||
| Dividends Paid | ||||||||||
| Retained Profit | 590,409 | 550,069 | -413,635 | -30,108 | ||||||
| Employee Costs | 1,314,956 | 847,908 | ||||||||
| Number Of Employees | 12 | 9 | 6 | 4 | 4 | 4 | 4 | 4 | 3 | |
| EBITDA* | 1,065,335 | 810,902 | -605,527 | -19,429 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 8,006 | 8,724 | 6,727 | 7,011 | 2,540 | |||||
| Intangible Assets | 232,604 | 457,870 | 438,045 | 364,125 | 339,503 | 319,706 | 307,497 | 41,499 | 112,933 | 52,499 |
| Investments & Other | 49 | 49 | 49 | 49 | 49 | |||||
| Debtors (Due After 1 year) | ||||||||||
| Total Fixed Assets | 240,610 | 466,594 | 444,772 | 371,136 | 342,043 | 319,755 | 307,546 | 41,548 | 112,982 | 52,548 |
| Stock & work in progress | 8,619,074 | 7,048,647 | 3,535,113 | 2,907,122 | 1,317,897 | 1,018,012 | 352,751 | 353,251 | ||
| Trade Debtors | 4,638,055 | 3,284,700 | 1,621,047 | 977,810 | 1,941,008 | 774,360 | 96,208 | 234,516 | 6,824 | |
| Group Debtors | ||||||||||
| Misc Debtors | 246,900 | 20,657 | 17,460 | 118,034 | 250,149 | 336,837 | 381,982 | 331,298 | 13,556 | |
| Cash | 135,781 | 93,564 | 16,180 | 6,275 | 257,428 | 78,560 | 23,899 | 87,226 | 4,121 | 692 |
| misc current assets | ||||||||||
| total current assets | 13,639,810 | 10,447,568 | 5,189,800 | 4,009,241 | 3,766,482 | 2,207,769 | 854,840 | 1,006,291 | 17,677 | 7,516 |
| total assets | 13,880,420 | 10,914,162 | 5,634,572 | 4,380,377 | 4,108,525 | 2,527,524 | 1,162,386 | 1,047,839 | 130,659 | 60,064 |
| Bank overdraft | 3,512,752 | 2,537,229 | 1,712,015 | 984,845 | ||||||
| Bank loan | ||||||||||
| Trade Creditors | 859,602 | 562,109 | 320,719 | 303,172 | 245,072 | 261,613 | 363,746 | 85,128 | 3,673 | 32,649 |
| Group/Directors Accounts | 3,847,896 | 2,855,733 | 279,113 | 85,797 | 2,767,695 | 2,336,442 | 1,135,881 | 768,057 | 8,630 | |
| other short term finances | ||||||||||
| hp & lease commitments | ||||||||||
| other current liabilities | 1,957,503 | 1,659,333 | 553,617 | 424,528 | 192,569 | 111,037 | 14,063 | 8,786 | 3,749 | |
| total current liabilities | 10,177,753 | 7,614,404 | 2,865,464 | 1,798,342 | 3,205,336 | 2,709,092 | 1,513,690 | 861,971 | 16,052 | 32,649 |
| loans | 636,696 | 824,196 | 845,796 | 1,274,196 | 636,696 | 636,696 | 636,696 | 636,696 | 151,800 | |
| hp & lease commitments | ||||||||||
| Accruals and Deferred Income | ||||||||||
| other liabilities | 34,500 | |||||||||
| provisions | 2,181 | 2,181 | 1,332 | 482 | ||||||
| total long term liabilities | 638,877 | 826,377 | 845,796 | 1,275,528 | 637,178 | 636,696 | 636,696 | 636,696 | 151,800 | 34,500 |
| total liabilities | 10,816,630 | 8,440,781 | 3,711,260 | 3,073,870 | 3,842,514 | 3,345,788 | 2,150,386 | 1,498,667 | 167,852 | 67,149 |
| net assets | 3,063,790 | 2,473,381 | 1,923,312 | 1,306,507 | 266,011 | -818,264 | -988,000 | -450,828 | -37,193 | -7,085 |
| total shareholders funds | 3,063,790 | 2,473,381 | 1,923,312 | 1,306,507 | 266,011 | -818,264 | -988,000 | -450,828 | -37,193 | -7,085 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | 840,357 | 738,606 | -611,027 | -32,255 | ||||||
| Depreciation | 3,846 | 3,227 | 2,190 | 985 | 572 | |||||
| Amortisation | 221,132 | 69,069 | 56,080 | 49,182 | 43,454 | 44,203 | 22,355 | 5,500 | 12,826 | 2,501 |
| Tax | -198,085 | -126,677 | 236,069 | 7,527 | ||||||
| Stock | 1,570,427 | 3,513,534 | 627,991 | 1,589,225 | 299,885 | 665,261 | -500 | 353,251 | ||
| Debtors | 1,579,598 | 1,666,850 | 542,663 | -1,095,313 | 1,079,960 | 633,007 | -87,624 | 552,258 | 6,732 | 6,824 |
| Creditors | 297,493 | 241,390 | 17,547 | 58,100 | -16,541 | -102,133 | 278,618 | 81,455 | -28,976 | 32,649 |
| Accruals and Deferred Income | 298,170 | 1,105,716 | 129,089 | 231,959 | 81,532 | 96,974 | 5,277 | 5,037 | 3,749 | |
| Deferred Taxes & Provisions | 2,181 | -1,332 | 850 | 482 | ||||||
| Cash flow from operations | -1,687,112 | -3,146,872 | -1,188,475 | -43,861 | ||||||
| Investing Activities | ||||||||||
| capital expenditure | ||||||||||
| Change in Investments | -49 | 49 | ||||||||
| cash flow from investments | ||||||||||
| Financing Activities | ||||||||||
| Bank loans | ||||||||||
| Group/Directors Accounts | 992,163 | 2,576,620 | 193,316 | -2,681,898 | 431,253 | 1,200,561 | 367,824 | 759,427 | 8,630 | |
| Other Short Term Loans | ||||||||||
| Long term loans | -187,500 | -21,600 | -428,400 | 637,500 | 484,896 | 151,800 | ||||
| Hire Purchase and Lease Commitments | ||||||||||
| other long term liabilities | -34,500 | 34,500 | ||||||||
| share issue | ||||||||||
| interest | -52,038 | -61,860 | -38,677 | -5,380 | ||||||
| cash flow from financing | 752,625 | 2,493,160 | 1,205,646 | 120,550 | ||||||
| cash and cash equivalents | ||||||||||
| cash | 42,217 | 77,384 | 9,905 | -251,153 | 178,868 | 54,661 | -63,327 | 83,105 | 3,429 | 692 |
| overdraft | 975,523 | 825,214 | 727,170 | 984,845 | ||||||
| change in cash | -933,306 | -747,830 | -717,265 | -1,235,998 | 178,868 | 54,661 | -63,327 | 83,105 | 3,429 | 692 |
flamingo pharma (uk) ltd Credit Report and Business Information
Flamingo Pharma (uk) Ltd Competitor Analysis
Perform a competitor analysis for flamingo pharma (uk) ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in HA1 area or any other competitors across 12 key performance metrics.
flamingo pharma (uk) ltd Ownership
FLAMINGO PHARMA (UK) LTD group structure
Flamingo Pharma (Uk) Ltd has no subsidiary companies.
Ultimate parent company
FLAMINGO PHARMACEUTICALS LTD
#0096811
1 parent
FLAMINGO PHARMA (UK) LTD
09006526
flamingo pharma (uk) ltd directors
Flamingo Pharma (Uk) Ltd currently has 3 directors. The longest serving directors include Pranay Thacker (Apr 2014) and Miss Miloni Virani (Feb 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Pranay Thacker | United Kingdom | 38 years | Apr 2014 | - | Director |
| Miss Miloni Virani | United Kingdom | 43 years | Feb 2022 | - | Director |
| Mr Ashwin Thacker | United Kingdom | 70 years | Mar 2023 | - | Director |
P&L
March 2024turnover
27.5m
+67%
operating profit
840.4k
+14%
gross margin
15.2%
+22.19%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
3.1m
+0.24%
total assets
13.9m
+0.27%
cash
135.8k
+0.45%
net assets
Total assets minus all liabilities
Similar Companies
flamingo pharma (uk) ltd company details
company number
09006526
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
April 2014
age
11
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
JOHN CUMMING ROSS LIMITED
address
first floor kirkland house, 11-15 peterborough road, harrow, middlesex, HA1 2AX
Bank
-
Legal Advisor
-
flamingo pharma (uk) ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to flamingo pharma (uk) ltd. Currently there are 2 open charges and 0 have been satisfied in the past.
flamingo pharma (uk) ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for FLAMINGO PHARMA (UK) LTD. This can take several minutes, an email will notify you when this has completed.
flamingo pharma (uk) ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
